Patent SG-11201810694W-A (SG)
Title: Use of biomarkers in determining susceptibility to disease treatment
Inventor: IYER NARAYANAN GOPALAKRISHNA
IPC: C12Q1/68
Filed: 2017-06-05
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111 IIIIIIIII10101111111111111110111011111111011111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/209697 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C12Q 1/68 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/SG2017/050284 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 05 June 2017 (05.06.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English — with sequence listing part of description (Rule 5.2(a)) (26) Publication Language: English (30) Priority Data: 62/345,081 03 June 2016 (03.06.2016) US (71) Applicant: SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singapore 168753 (SG). (72) Inventors: IYER, Narayanan Gopalakrishna; c/o Na- tional Cancer Centre Singapore, 11 Hospital Drive, Singa- pore 169610 (SG). TAN, Daniel Shao-Weng; c/o Nation- — al Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG). — = (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; = P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States indicated, (84) (unless otherwise for every = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, UG, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 N (54) Title: USE OF BIOMARKERS IN DETERMINING SUSCEPTIBILITY TO DISEASE TREATMENT (57) : The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment ON with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding N RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, ---. and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic I N alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a 1-1 © method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense ei strand of an oncogene. C